Top

Published in:

Open Access 01-01-2016 | Review Article

Cardiac dyssynchrony and response to cardiac resynchronisation therapy in heart failure: can genetic predisposition play a role?

Authors: N. Lahrouchi, C.R. Bezzina

Published in: Netherlands Heart Journal | Issue 1/2016

Abstract

Cardiac resynchronisation therapy (CRT) is an accepted treatment for heart failure patients with depressed left ventricular (LV) function and dyssynchrony. However, despite better clinical outcome and improved cardiac function after CRT in the majority of eligible heart failure patients, a large proportion of implanted patients do not seem to benefit clinically from this therapy. In this review we consider whether genetic factors may play a role in modulating response to CRT and summarise the few genetic studies that have investigated the role of genetic variation in candidate genes.

Kirk JA, Kass DA. Electromechanical dyssynchrony and resynchronisation of the failing heart. Circ Res. 2013;113:765–76.PubMedCrossRef

Prinzen FW, Vernooy K, Auricchio A. Cardiac resynchronisation therapy: state-of-the-art of current applications, guidelines, ongoing trials, and areas of controversy. Circulation. 2013;128:2407–18.PubMedCrossRef

Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronisation therapy: the Task Force on cardiac pacing and resynchronisation therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association. Eur Heart J. 2013;34:2281–329.PubMedCrossRef

Leyva F, Nisam S, Auricchio A. 20 years of cardiac resynchronisation therapy. J Am Coll Cardiol. 2014;64:1047–58.PubMedCrossRef

Bax JJ, Gorcsan J. Echocardiography and noninvasive imaging in cardiac resynchronisation therapy: results of the PROSPECT (Predictors of Response to Cardiac Resynchronisation Therapy) study in perspective. J Am Coll Cardiol. 2009;53:1933–43.PubMedCrossRef

Auricchio A, Prinzen FW. Non-responders to cardiac resynchronisation therapy: the magnitude of the problem and the issues. Circ J. 2011;75:521–7.PubMedCrossRef

Lee DS, Pencina MJ, Benjamin EJ, et al. Association of parental heart failure with risk of heart failure in offspring. N Engl J Med. 2006;355:138–47.PubMedCrossRef

Friedlander Y, Siscovick DS, Arbogast P, et al. Sudden death and myocardial infarction in first degree relatives as predictors of primary cardiac arrest. Atherosclerosis. 2002;162:211–6.PubMedCrossRef

Dekker LRC, Bezzina CR, Henriques JPS, et al. Familial sudden death is an important risk factor for primary ventricular fibrillation: a case-control study in acute myocardial infarction patients. Circulation. 2006;114:1140–5.PubMedCrossRef

10.

Kolder ICRM, Tanck MWT, Bezzina CR. Common genetic variation modulating cardiac ECG parameters and susceptibility to sudden cardiac death. J Mol Cell Cardiol. 2012;52:620–9.PubMedCrossRef

11.

Post WS, Larson MG, Myers RH, Galderisi M, Levy D. Heritability of left ventricular mass: the Framingham Heart Study. Hypertension. 1997;30:1025–8.PubMedCrossRef

12.

Dorn GW. The genomic architecture of sporadic heart failure. Circ Res. 2011;108:1270–83.PubMedPubMedCentralCrossRef

13.

Sinner MF, Ellinor PT, Meitinger T, Benjamin EJ, Kääb S. Genome-wide association studies of atrial fibrillation: past, present, and future. Cardiovasc Res. 2011;89:701–9.PubMedPubMedCentralCrossRef

14.

Bezzina CR, Lahrouchi N, Priori SG. Genetics of sudden cardiac death. Circ Res. 2015;116:1919–36.PubMedCrossRef

15.

Frazer KA, Murray SS, Schork NJ, Topol EJ. Human genetic variation and its contribution to complex traits. Nat Rev Genet. 2009;10:241–51.PubMedCrossRef

16.

De Maria R, Landolina M, Gasparini M, et al. Genetic variants of the renin-angiotensin-aldosterone system and reverse remodeling after cardiac resynchronisation therapy. J Card Fail. 2012;18:762–8.PubMedCrossRef

17.

Messaoudi S, Azibani F, Delcayre C, Jaisser F. Aldosterone, mineralocorticoid receptor, and heart failure. Mol Cell Endocrinol. 2012;350:266–72.PubMedCrossRef

18.

Bleumink GS, Schut AFC, Sturkenboom MCJM, Deckers JW, Duijn CM van, Stricker BHC. Genetic polymorphisms and heart failure. Genet Med. 2004;6:465–74.PubMedCrossRef

19.

Schmitz B, De Maria R, Gatsios D, et al. Identification of genetic markers for treatment success in heart failure patients: insight from cardiac resynchronisation therapy. Circ Cardiovasc Genet. 2014;7:760–70.PubMedCrossRef

20.

Chakir K, Daya SK, Aiba T, et al. Mechanisms of enhanced beta-adrenergic reserve from cardiac resynchronisation therapy. Circulation. 2009;119:1231–40.PubMedPubMedCentralCrossRef

21.

Vanderheyden M, Mullens W, Delrue L, et al. Endomyocardial upregulation of beta1 adrenoreceptor gene expression and myocardial contractile reserve following cardiac resynchronisation therapy. J Card Fail. 2008;14:172–8.PubMedCrossRef

22.

Pezzali N, Curnis A, Specchia C, et al. Adrenergic receptor gene polymorphism and left ventricular reverse remodelling after cardiac resynchronisation therapy: preliminary results. Europace. 2013;15:1475–81.PubMedCrossRef

23.

Kaye DM, Smirk B, Williams C, Jennings G, Esler M, Holst D. Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics. 2003;13:379–82.PubMedCrossRef

24.

Metra M, Covolo L, Pezzali N, et al. Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. Cardiovasc Drugs Ther. 2010;24:49–60.PubMedCrossRef

25.

Taylor MR, Sun AY, Davis G, Fiuzat M, Liggett SB, Bristow MR. Race, common genetic variation, and therapeutic response disparities in heart failure. JACC Heart Fail. 2014;2:561–72.PubMedPubMedCentralCrossRef

26.

Sotoodehnia N, Siscovick DS, Vatta M, et al. Beta2-adrenergic receptor genetic variants and risk of sudden cardiac death. Circulation. 2006;113(15):1842–8.PubMedCrossRef

27.

Marfella R, Di Filippo C, Potenza N, et al. Circulating microRNA changes in heart failure patients treated with cardiac resynchronisation therapy: responders vs. non-responders. Eur J Heart Fail. 2013;15:1277–88.PubMedCrossRef

28.

Melman YF, Shah R, Danielson K, et al. Circulating MicroRNA-30d is Associated with Response to Cardiac Resynchronisation Therapy in Heart Failure and Regulates Cardiomyocyte Apoptosis: a Translational Pilot Study. Circulation. 2015;131:2202–16.PubMedCrossRef

29.

Fichtlscherer S, Zeiher AM, Dimmeler S. Circulating microRNAs: biomarkers or mediators of cardiovascular diseases? Arterioscler Thromb Vasc Biol. 2011;31:2383–90.PubMedCrossRef

30.

Dorn GW. Great Expectations: MicroRNA-30d and Cardiac Resynchronisation Therapy. Circulation. 2015;131:2172–5.PubMedCrossRef

31.

Iyengar S, Haas G, Lamba S, et al. Effect of cardiac resynchronisation therapy on myocardial gene expression in patients with nonischemic dilated cardiomyopathy. J Card Fail. 2007;13:304–11.PubMedCrossRef

32.

Mullens W, Bartunek J, Wilson Tang WH, et al. Early and late effects of cardiac resynchronisation therapy on force-frequency relation and contractility regulating gene expression in heart failure patients. Heart Rhythm. 2008;5:52–9.PubMedCrossRef

33.

Vanderheyden M, Mullens W, Delrue L, et al. Myocardial gene expression in heart failure patients treated with cardiac resynchronisation therapy responders versus nonresponders. J Am Coll Cardiol. 2008;51:129–36.PubMedCrossRef

34.

Barth AS, Aiba T, Halperin V, et al. Cardiac resynchronisation therapy corrects dyssynchrony-induced regional gene expression changes on a genomic level. Circ Cardiovasc Genet. 2009;2(4):371–8.PubMedPubMedCentralCrossRef

35.

Cho H, Barth AS, Tomaselli GF. Basic science of cardiac resynchronisation therapy: molecular and electrophysiological mechanisms. Circ Arrhythm Electrophysiol. 2012;5:594–603.PubMedPubMedCentralCrossRef

36.

Di Biase L, Gasparini M, Lunati M, et al. Antiarrhythmic effect of reverse ventricular remodeling induced by cardiac resynchronisation therapy: the InSync ICD (Implantable Cardioverter-Defibrillator) Italian Registry. J Am Coll Cardiol. 2008;52:1442–9.PubMedCrossRef

37.

Harper AR, Topol EJ. Pharmacogenomics in clinical practice and drug development. Nat Biotechnol.2012;30:1117–24. (Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved).PubMedCrossRef

Title: Cardiac dyssynchrony and response to cardiac resynchronisation therapy in heart failure: can genetic predisposition play a role?
Authors: N. Lahrouchi
C.R. Bezzina
Publication date: 01-01-2016
Publisher: Bohn Stafleu van Loghum
Published in: Netherlands Heart Journal / Issue 1/2016
Print ISSN: 1568-5888
Electronic ISSN: 1876-6250
DOI: https://doi.org/10.1007/s12471-015-0766-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cardiac dyssynchrony and response to cardiac resynchronisation therapy in heart failure: can genetic predisposition play a role?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2016

Echo response and clinical outcome in CRT patients

Patients predict their own outcome with CRT

Pathophysiology of dyssynchrony: of squirrels and broken bones

Current aspects of cardiac resynchronisation therapy

To implant or not to implant?

The influence of right ventricular stimulation on acute response to cardiac resynchronisation therapy